Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more

GSK seeking approval of HIF-PH inhibitor in Japan
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it submitted an NDA to Japan's Ministry of Health, Labour and Welfare for daprodustat to treat patients with renal anemia due to chronic kidney disease (CKD), its first application for the HIF-PH inhibitor worldwide. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) has commercialization

Read the full 548 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE